One of those studies [26] revealed that MSH2 carriers (9%) are at higher risk for gastric cancer than MLH1 carriers (4.8%) and showed that MSH6 carriers have not developed gastric cancer during their lifetime. Here, MSH2 is linked to gastric cancer.